A real-world comparison of alectinib, brigatinib, and lorlatinib found no significant differences in clinical or economic outcomes among patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (mNSCLC).
A real-world comparison of alectinib, brigatinib, and lorlatinib found no significant differences in clinical or economic outcomes among patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (mNSCLC).
Researchers found that among patients with advanced non-small cell lung cancer (NSCLC), those living in the US had higher rates of health care utilization and higher care costs, illustrating the substantial economic burden associated with...
Researchers found that among patients with advanced non-small cell lung cancer (NSCLC), those living in the US had higher rates of health care utilization and higher care costs, illustrating the substantial economic burden associated with...
In the phase 3 LAURA clinical trial, osimertinib demonstrated a tolerable safety profile when used to treat patients with non–small cell lung cancer (NSCLC) after definitive chemoradiotherapy (CRT).
In the phase 3 LAURA clinical trial, osimertinib demonstrated a tolerable safety profile when used to treat patients with non–small cell lung cancer (NSCLC) after definitive chemoradiotherapy (CRT).
A real-world study found that using immune checkpoint inhibitors (ICIs) to treat non–small cell lung cancer (NSCLC) expanded the use of systemic anticancer treatment (SACT) and significantly increased survival outcomes, even among patients...
A real-world study found that using immune checkpoint inhibitors (ICIs) to treat non–small cell lung cancer (NSCLC) expanded the use of systemic anticancer treatment (SACT) and significantly increased survival outcomes, even among patients...
Datopotamab deruxtecan plus pembrolizumab, with or without platinum-based chemotherapy, produced durable responses and manageable safety across programmed death-ligand 1 expression levels in patients with advanced non–small cell lung cancer...
Datopotamab deruxtecan plus pembrolizumab, with or without platinum-based chemotherapy, produced durable responses and manageable safety across programmed death-ligand 1 expression levels in patients with advanced non–small cell lung cancer...
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Amivantamab plus lazertinib shows promising and durable activity in patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations, offering a potential new treatment option for...
Amivantamab plus lazertinib shows promising and durable activity in patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations, offering a potential new treatment option for...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
